非酒精性脂肪性肝病患者血清脂肪细胞因子研究进展*

doi:10.3969/j.issn.1672-5069.2014.03.034

Abstract

Abstract: Nonalcoholic fatty liver disease （NAFLD） is a part of hepatic manifestation of the metabolic syndrome. Its main features are fat deposition in liver and insulin resistance （IR）. Adipokines, a group of polypeptides secreted by adipocyte cells, play an important role in the pathogenesis of NAFLD and IR. In this paper,the focus is emphasized on the roles of adipokines in NAFLD,such as leptin, adiponectin, retinol binding protein 4,fibroblast growth factor 21,chemerin and other emerging factors.

Key words: Non-alcoholic fatty liver disease, Adipocytokines, Insulin resistance

Wang Ping, Li Qiang. Adipocytokines in nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 329-333.

References

[1] Myers MG,Cowley MA,Munzberg H, et al. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol,2008,70:537-556.
[2] 潘莉,韩真.脂肪细胞因子在非酒精性脂肪肝发病机制中的作用. 实用肝脏病杂志,2010,13（2）：151-154.
[3] 王永兵,宋红杰,王悟云,等.海门地区体检人群脂肪肝检出及危险因素分析. 实用肝脏病杂志,2006,9（6）：343-344.
[4] Ravussin E,Smith SR,Mitchell JA,et al. Enhanced weight loss with pramlintide/metreleptin:an integrated neurohormonal approach to obesity pharmacotherapy. Obesity（Silver Spring）,2009,17（9）:1736-1743.
[5] Safar Zadeh E,Lungu AO,Cochran EK,et al. The liver diseases of lipodystrophy:the long-term effect of leptin treatment. J Hepatol,2013,59（1）:131-137.
[6] Imajo K,Fujita K,Yoneda M,et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell metab,2012,16（1）:44-54.
[7] Kwon DH,Kang W,Nam YS,et al. Dietary protein restriction induces steatohepatitis and alters leptin/signal transducers and activators of transcription 3 signaling in lactating rats. J Nutrit Biochem,2012,23（7）:791-799.
[8] Kadowaki T,Yamauchi T,Kubota N,et al. Adiponectin and adiponectin receptors in insulin resistance,diabetes,and the metabolic syndrome. Clin Invest,2006,116（7）:1784-1792.
[9] 宋新文,申保生,王宏伟.非酒精性脂肪性肝病患者血清脂联素和瘦素水平变化. 实用肝脏病杂志,2013,16（2）：141-143.
[10] 杨瑞雪,马向华,沈捷. 脂联素和过氧化物酶体增殖物激活受体mRNA的表达与代谢综合征.医学研究生学报,2011,24（6）：578-581.
[11] 丁虹,黄飚,陈锦,等.非酒精性脂肪性肝病患者血清脂联素的检测意义. 实用肝脏病杂志,2011,14（6）：469-470.
[12] Liew PL,Chen CL,Lee YC,et al. Hepatic tumor necrosis factor-α,leptin and adiponectin expression in morbid obese patients:Clinicopathological correlations. Obesity Res Clin Pract,2012,6（1）:55-62.
[13] Koot BG,van der Baan-Slootweg OH,Bohte AE,et al.Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity,2013,21 （3）:583-590.
[14] Serrano A,Pavón FJ,Suarez J,et al. Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. Physiol Endocrinol Metab,2012,302 （7）:817-830.
[15] 李丽,闵若谦,展玉涛,等.血清视黄醇结合蛋白4对非酒精性脂肪性肝炎的诊断价值. 实用肝脏病杂志,2011,14（5）：351-353.
[16] Tan Y,Sun LQ,Kamal MA,et al. Suppression of retinol- binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. Biochim Biophys Acta,2011,1811（12）:1045-1053.
[17] 刘滨菘,李强,王薇,等.视黄醇结合蛋白4 与非酒精性脂肪肝病的相关研究. 中华内分泌代谢杂志,2013,29（1）：58-61.
[18] Petta S,Tripodo C,Grimaudo S,et al. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis,2011,43（5）:404-410.
[19] Nobili V,Alkhouri N,Alisi A,et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2009,7（5）:575-579.
[20] Woo YC,Xu A,Wang Y,et al. Fibroblast growth factor 21 as an emerging metabolic regulator:clinical perspectives. Clin Endocrinol （Oxf）,2013,78（4）:489-496.
[21] Coskun T, Bina HA,Schneider MA,et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology,2008,149（12）:6018-6027.
[22] Yang C,Lu W,Lin T,et al. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol,2013,86（9）:576-584.
[23] Li H,Dong K,Fang Q,et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease:a 3-year prospective study in China. Hepatology,2013,58（3）:557-563.
[24] Shen J,Chan HL,Wong GL,et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hetapol,2012,58（6）:1363-1370.
[25] Li X,Fan X,Ren F,et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diab Res Clin Pract,2011,93（1）:10-16.
[26] Goralski KB,McCarthy TC,Hanniman EA,et al. Chemerin,a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem,2007,282（38）:28175-28188.
[27] Krautbauer S,Wanninger J,Eisinger K,et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol,2013,95（2）:199-205.
[28] Henrike S,Adeline D,Christine P,et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. Clin Endocrinol Metab,2010,95（6）:2892-2896.
[29] Docke S,Lock JF,Birkenfeld AL,et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol,2013,169（5）:547-557.
[30] Wanninger J,Bauer S,Eisinger K, et al. Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol,2012,349（2）:248-254.

Adipocytokines in nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[2]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[3]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[4]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[5]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[8]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[9]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[10]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[11]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[12]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[13]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[14]	Ge Jianxiang, Sun Yezi, Zhao Yun.. Application of entecavir in the treatment of patients with HBV-related cirrhosis complicated by hepatogenous diabetes and its influence on indexes of glucose metabolism [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 677-680.
[15]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.